ReviewDiscover mental health2025
Modulation of NF-κB signaling pathway by tocotrienol in neurodegenerative diseases.
Review in Discover mental health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Exploring the role of tocotrienol-rich fraction (TRF) in ameliorating neuroinflammation.Inflammopharmacology · 2026Article
- Targeting the Sleep-Glymphatic-Vascular Continuum in Cerebral Small Vessel Disease: A Nutritional Perspective on Neuroprotective Potential of Tocotrienols (T3).Life (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Neurodegenerative diseases (ND) are a form of non-communicable disease that have placed immense social and financial burdens on society. The number of people affected by ND is an ongoing trend due to the global issue of an ageing population. Hence, more effort should be made to treat ND, so alternative options like natural components are considered. Tocotrienol (T3) is a form of vitamin E that possesses many beneficial properties, such as antioxidant, anti-cancer and anti-inflammatory properties. In recent years, many clinical studies revolving around diseases such as neurodegenerative diseases, cardiovascular diseases and osteoporosis appear to suggest that T3 supplementation can be effective in alleviating the symptoms of these diseases. Given that T3 has multiple health benefits and is a potential therapeutic agent for ND, it is important to understand the mechanism through which T3 exerts the beneficial works. One such pathway is the NF-κB signalling pathway, which is closely associated with neuroinflammation and neurodegenerative diseases. Understanding the mechanism of how T3 affects this pathway could be crucial to demonstrate the efficacy of T3 in the management of ND.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.